Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $15.40 Consensus PT from Brokerages

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) has been assigned an average recommendation of “Buy” from the seven analysts that are covering the company, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $15.40.

A number of research firms recently issued reports on TNYA. Canaccord Genuity Group lowered their target price on Tenaya Therapeutics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, March 20th. Chardan Capital reissued a “buy” rating and set a $20.00 target price on shares of Tenaya Therapeutics in a research note on Thursday, March 21st. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a research note on Tuesday, March 19th.

Tenaya Therapeutics Price Performance

Shares of TNYA stock opened at $4.47 on Friday. The stock has a market cap of $350.98 million, a PE ratio of -2.68 and a beta of 2.60. The stock has a 50-day moving average of $5.29 and a 200-day moving average of $3.55. Tenaya Therapeutics has a one year low of $1.66 and a one year high of $8.09.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings results on Monday, March 18th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.05. As a group, research analysts anticipate that Tenaya Therapeutics will post -1.7 earnings per share for the current year.

Insiders Place Their Bets

In other Tenaya Therapeutics news, insider Timothy Hoey sold 6,569 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $5.34, for a total transaction of $35,078.46. Following the completion of the transaction, the insider now owns 236,146 shares of the company’s stock, valued at approximately $1,261,019.64. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, major shareholder Group Gp Lp Column III purchased 2,222,222 shares of Tenaya Therapeutics stock in a transaction on Monday, February 12th. The stock was purchased at an average price of $4.50 per share, with a total value of $9,999,999.00. Following the transaction, the insider now directly owns 13,599,275 shares in the company, valued at approximately $61,196,737.50. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Timothy Hoey sold 6,569 shares of the stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $5.34, for a total value of $35,078.46. Following the completion of the sale, the insider now directly owns 236,146 shares of the company’s stock, valued at approximately $1,261,019.64. The disclosure for this sale can be found here. Insiders sold a total of 20,908 shares of company stock valued at $122,867 in the last quarter. 33.83% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Tenaya Therapeutics

Several large investors have recently made changes to their positions in the stock. HighPoint Advisor Group LLC acquired a new stake in shares of Tenaya Therapeutics in the 4th quarter valued at approximately $228,000. Vanguard Group Inc. boosted its holdings in shares of Tenaya Therapeutics by 13.4% in the 4th quarter. Vanguard Group Inc. now owns 2,459,444 shares of the company’s stock valued at $7,969,000 after buying an additional 291,576 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Tenaya Therapeutics by 1.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,544,543 shares of the company’s stock valued at $14,725,000 after buying an additional 69,377 shares during the last quarter. GSA Capital Partners LLP boosted its holdings in shares of Tenaya Therapeutics by 29.5% in the 4th quarter. GSA Capital Partners LLP now owns 470,845 shares of the company’s stock valued at $1,526,000 after buying an additional 107,352 shares during the last quarter. Finally, Bridgeway Capital Management LLC boosted its holdings in shares of Tenaya Therapeutics by 6.1% in the 4th quarter. Bridgeway Capital Management LLC now owns 193,000 shares of the company’s stock valued at $625,000 after buying an additional 11,100 shares during the last quarter. Institutional investors and hedge funds own 90.54% of the company’s stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.